Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Cash from Operations for 3 consecutive years, with 40875000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 9.06% to 40875000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 147783000.0 through Dec 2025, up 6.8% year-over-year, with the annual reading at 147783000.0 for FY2025, 6.8% up from the prior year.
  • Cash from Operations hit 40875000.0 in Q4 2025 for NewAmsterdam Pharma, down from 32769000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 12502000.0 in Q3 2024 to a low of 54602000.0 in Q1 2024.
  • Historically, Cash from Operations has averaged 37297083.33 across 3 years, with a median of 36974500.0 in 2024.
  • Biggest five-year swings in Cash from Operations: soared 73.39% in 2024 and later tumbled 162.11% in 2025.
  • Year by year, Cash from Operations stood at 33074000.0 in 2023, then dropped by 13.32% to 37481000.0 in 2024, then decreased by 9.06% to 40875000.0 in 2025.
  • Business Quant data shows Cash from Operations for NAMS at 40875000.0 in Q4 2025, 32769000.0 in Q3 2025, and 37671000.0 in Q2 2025.